Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy

Journal of the National Cancer Institute

Volumn 103, Issue 10, 2011, Pages 817-825

  Wu, Xifeng ^a   Ye, Yuanqing ^a   Rosell, Rafael ^b   Amos, Christopher I ^a   Stewart, David J ^a   Hildebrandt, Michelle A T ^a   Roth, Jack A ^a   Minna, John D ^c   Gu, Jian ^a   Lin, Jie ^a   Buch, Shama C ^d   Nukui, Tomoko ^d   Ramirez Serrano, Jose Luis ^b   Taron, Miquel ^b   Cassidy, Adrian ^a   Lu, Charles ^a   Chang, Joe Y ^a   Lippman, Scott M ^a   Hong, Waun Ki ^a   Spitz, Margaret R ^a   Romkes, Marjorie ^d   Yang, Ping ^e   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE LIKE RECEPTOR 1; CISPLATIN; DOCETAXEL; GENE PRODUCT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CMKLR1 GENE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTORS, CHEMOKINE; REPRODUCIBILITY OF RESULTS; ROC CURVE; SMOKING; TREATMENT OUTCOME;

EID: 79957468312     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr075     Document Type: Article

References (41)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.
2. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic poly-morphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22(13):2594- 2601. (Pubitemid 41103746)
3. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797-1803. (Pubitemid 351469466)
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemo-therapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98. (Pubitemid 34438899)
5. Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 2006;106(11):2421- 2427. (Pubitemid 43787666)
6. Kim SH, Juhnn YS, Song YS. Akt involvement in paclitaxel chemoresis-tance of human ovarian cancer cells. Ann N Y Acad Sci. 2007;1095(1):82-89.
7. Matakidou A, el Galta R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16(19):2333-2340. (Pubitemid 47423899)
8. Wu X, Lu C, Ye Y, et al. Germline genetic variations in drug action path-ways predict clinical outcomes in advanced lung cancer treated with plati-num-based chemotherapy. Pharmacogenet Genomics. 2008;18(11):955-965.
9. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40(5):616-622. (Pubitemid 351601203)
10. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633-637. (Pubitemid 351483367)
11. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40(12):1404-1406.
12. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nico-tine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638-642. (Pubitemid 351483366)
13. Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008;40(12):1407-1409.
14. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452-462.
15. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575. (Pubitemid 47330214)
16. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909. (Pubitemid 44141658)
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265. (Pubitemid 40202029)
18. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009;5(7):745-755.
19. Dolan ME, Newbold KG, Nagasubramanian R, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004;64(12):4353-4356. (Pubitemid 38802443)
20. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007;81(3):427-437. (Pubitemid 47330203)
21. Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics. 2008;18(3):253-262. (Pubitemid 351323240)
22. Muruganandan S, Roman AA, Sinal CJ. Role of chemerin/CMKLR1 sig-naling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res. 2010;25(2):222-234.
23. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148(10):4687-4694. (Pubitemid 47481514)
24. Roh SG, Song SH, Choi KC, et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362(4):1013-1018.
25. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198(7):977-985. (Pubitemid 37248614)
26. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem. 2010;285(5):3451-3461.
27. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: Chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun. 2010;391(4):1762-1768.
28. Joshi N, Johnson LL, Wei WQ, et al. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006;66(13):6851-6860. (Pubitemid 44085646)
29. Westergaard UB, Sorensen ES, Hermey G, et al. Functional organization of the sortilin Vps10p domain. J Biol Chem. 2004;279(48):50221-50229. (Pubitemid 39577836)
30. Willnow TE, Petersen CM, Nykjaer A. VPS10P-domain receptors-regulators of neuronal viability and function. Nat Rev Neurosci. 2008;9(12):899-909.
31. Hermey G, Sjogaard SS, Petersen CM, Nykjaer A, Gliemann J. Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem J. 2006;395(2):\285-293.
32. Hampe W, Rezgaoui M, Hermans-Borgmeyer I, Schaller HC. The genes for the human VPS10 domain-containing receptors are large and contain many small exons. Hum Genet. 2001;108(6):529-536. (Pubitemid 32700356)
33. Hermey G, Plath N, Hubner CA, Kuhl D, Schaller HC, Hermans-Borgmeyer I. The three sorCS genes are differentially expressed and regulated by synaptic activity. J Neurochem. 2004;88(6):1470-1476. (Pubitemid 38366923)
34. Rezgaoui M, Hermey G, Riedel IB, Hampe W, Schaller HC, Hermans-Borgmeyer I. Identification of SorCS2, a novel member of the VPS10 domain containing receptor family, prominently expressed in the devel-oping mouse brain. Mech Dev. 2001;100(2):335-338. (Pubitemid 32109345)
35. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clin-ical outcome in breast cancer. Nat Med. 2008;14(5):518-527. (Pubitemid 351655218)
36. Watanabe H, Mogushi K, Miura M, et al. Prediction of lymphatic metas-tasis based on gene expression profile analysis after brachytherapy for early-stage oral tongue carcinoma. Radiother Oncol. 2008;87(2):237-242.
37. Jung JJ, Jeung HC, Chung HC, et al. In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Genomics. 2009;93(1):52-61.
38. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key path-ways in lung adenocarcinoma. Nature. 2008;455(7216):1069-1075.
39. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910-919. (Pubitemid 351397090)
40. Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010;102(21):1618-1627.
41. Burdett S, Stephens R, Stewart L, et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617-4625.